Discontinuation report DURATOCIN

Last updated on 2021-05-19 History
Report ID 135523
Drug Identification Number 02231593
Brand name DURATOCIN
Common or Proper name carbetocin injection
Company Name FERRING INC
Market Status CANCELLED POST MARKET
Active Ingredient(s) CARBETOCIN
Strength(s) 100MCG
Dosage form(s) LIQUID SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size Boxes of 5 ampoules
ATC code H01BB
ATC description POSTERIOR PITUITARY LOBE HORMONES
Reason for discontinuation Business reasons
Anticipated discontinuation date 2021-05-15
Actual discontinuation date 2021-05-18
Remaining supply date 2021-05-04
Discontinuation status Discontinued
Discontinuation decision reversal No
Information on remaining supply
Company comments Substitute with DURATOCIN 100 mcg room temperature stable vials, 1 mL vial, 100 mcg / mL; UPC 779170192852; DIN 02496526. Store at: 15°C to 30°C. Available now and in stock; DURATOCIN (carbetocin injection) room temperature stable vials are indicated for the prevention of postpartum haemorrhage by controlling uterine atony. DURATOCIN room temperature stable vials have the same efficacy and safety features as ampoules with expanded indication for vaginal deliveries. Contact Information: www.maternalhealth.ca Med Info Phone 1-866-384-1314; email : ca0-medicalinformati@ferring.com
Health Canada comments
Tier 3 Status No
Contact Address 200 YORKLAND BLVD
TORONTO, ONTARIO
CANADA M2J 5C1
Company contact information 1-800-263-4057

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v10 2021-05-19 English Compare
v9 2021-05-18 French Compare
v8 2021-05-18 English Compare
v7 2021-05-18 French Compare
v6 2021-05-18 English Compare
v5 2021-04-29 French Compare
v4 2021-04-29 English Compare
v3 2021-03-11 French Compare
v2 2021-03-11 French Compare
v1 2021-03-11 English Compare

Showing 1 to 10 of 10